AM 404 manufacturers
- AM 404
-
- $10.00
-
2026-07-14
- CAS:183718-77-6
- Min. Order: 1ASSAYS
- Purity: 99%
- Supply Ability: 1 ton
|
| Product Name: | AM 404 | | Synonyms: | N-(4-HYDROXYPHENYL)-ARACHIDONAMIDE;N-(4-HYDROXYPHENYL) ARACHIDONOYLAMIDE;N-(4-HYDROXYPHENYL)ARACHIDONYLAMIDE;N-(4-HYDROXYPHENYL)-5Z,8Z,11Z,14Z-EICOSATETRAENAMIDE;N-(4-HYDROXYPHENYL)-5Z,8Z,11Z,14Z-EICOSATETRENAMIDE;ARACHIDONOYLAMIDE, N-(4-HYDROXYPHENYL);AM 404;(5Z,8Z,11Z,14Z)-N-(4-Hydroxyphenyl)-5,8,11,14-eicosatetraenaMide | | CAS: | 183718-77-6 | | MF: | C26H37NO2 | | MW: | 395.58 | | EINECS: | 200-578-6 | | Product Categories: | Aromatics;Fatty Acid Derivatives & Lipids;Glycerols;Inhibitors;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals | | Mol File: | 183718-77-6.mol |  |
| | AM 404 Chemical Properties |
| Boiling point | 579.4±50.0 °C(Predicted) | | density | 1.007±0.06 g/cm3(Predicted) | | Fp | 14 °C | | storage temp. | -20°C | | solubility | ethanol: 24 mg/mL Photosensitive solution. | | form | solution | | pka | 10.11±0.26(Predicted) | | color | Colorless to light yellow | | InChIKey | IJBZOOZRAXHERC-DOFZRALJSA-N | | SMILES | CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1 |
| Hazard Codes | F | | Risk Statements | 36/37/38-11 | | Safety Statements | 7-16 | | RIDADR | UN 1170 3/PG 2 | | WGK Germany | 1 | | Storage Class | 3 - Flammable liquids | | Hazard Classifications | Eye Irrit. 2
Flam. Liq. 2 |
| | AM 404 Usage And Synthesis |
| Uses | It is a metabolite of the well-known analgesic Paracetamol.
ase (FAAH) in vivo. | | Uses | Potentiates the activity of endogenous anandamide by blocking its re-uptake into presynaptic membranes. AM404 selectively inhibits the carrier-mediated transport of anandamide without affecting anandamide hydrolysis. | | in vivo | AM404 (1-5 mg/kg, i.p.) exerts dose-dependent anxiolytic-like effects in the three models: elevated plus maze, defensive withdrawal and separation-induced ultrasonic vocalizations. | Animal Model: | Adult male Sprague-Dawley rats (250-300g)[2] | | Dosage: | 2.5-10mg/kg | | Administration: | Intraperitoneal (i.p.) | | Result: | Caused a dose-dependent increase in anandamide levels in prefrontal cortex, hippocampus and thalamus.
|
| | storage | -20°C |
| | AM 404 Preparation Products And Raw materials |
|